Experimental cancer combo shows promise but trial halted early
NCT ID NCT04972110
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug, RP-3500 (camonsertib), combined with existing PARP inhibitors (niraparib or olaparib) in 156 adults with advanced solid tumors that have specific genetic markers. The goal was to find safe doses and see if the combination could shrink tumors. However, the study was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RP-3500 (camonsertib) combined with niraparib or olaparib
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced cancers that have specific genetic changes and have stopped responding to standard therapies.
What could go wrong
The trial was terminated early, so results are limited. The combination may cause significant side effects, and it is unclear if it will work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Participating Site # 1001
Houston, Texas, 77030, United States
-
Participating Site # 1008
New York, New York, 10032, United States
-
Participating Site # 1013
Salt Lake City, Utah, 84112, United States
-
Participating Site # 1016
Rochester, Minnesota, 55905, United States
-
Participating Site #1009
Baltimore, Maryland, 21205, United States
-
Participating Site #1012
New Haven, Connecticut, 06511, United States
-
Participating Site #1015
Ann Arbor, Michigan, 48109, United States
-
Participating Site #1017
Jacksonville, Florida, 32224, United States
-
Participating Site #1018
Phoenix, Arizona, 97401, United States
-
Participating Site #1025
San Francisco, California, 94158, United States
-
Participating Site #1026
New York, New York, 10029, United States
-
Participating Site #1028
Aurora, Colorado, 80012, United States
-
Participating Site #1029
Eugene, Oregon, 97401, United States